| First Author | Inoue A | Year | 1999 |
| Journal | J Immunol | Volume | 163 |
| Issue | 11 | Pages | 6180-6 |
| PubMed ID | 10570309 | Mgi Jnum | J:58648 |
| Mgi Id | MGI:1349310 | Doi | 10.4049/jimmunol.163.11.6180 |
| Citation | Inoue A, et al. (1999) Effect of anti-B7-1 and anti-B7-2 mAb on Theiler's murine encephalomyelitis virus-induced demyelinating disease. J Immunol 163(11):6180-6 |
| abstractText | We examined the role of B7-1 and B7-2, costimulatory molecules critical to full activation of T cells, in the development of Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD). Treatment with mAbs to B7-1 resulted in significant suppression of the development of this disease both clinically and histologically. In mice treated with these mAbs, the production of TNF-alpha and IFN-gamma in the spleen cells was decreased. The delayed-type hypersensitivity and T cell proliferative response specific for TMEV were decreased by this treatment. In contrast, treatment with Abs to B7-2, resulted in no effect on TMEV-IDD. These data suggest that B7-1 is critically involved in the pathogenesis of TMEV-IDD and that Abs to B7-1 could be a novel therapeutic approach in the clinical treatment of demyelinating diseases such as human multiple sclerosis. |
